Lurbinectedin
- Generic Name
- Lurbinectedin
- Brand Names
- Zepzelca, 赞必佳
- Drug Type
- Small Molecule
- Chemical Formula
- C41H44N4O10S
- CAS Number
- 497871-47-3
- Unique Ingredient Identifier
- 2CN60TN6ZS
- Background
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin (trabectedin), an anticancer agent found in extracts of the tunicate Ecteinascid...
- Indication
Lurbinectedin is indicated for the treatment of adult patients with metastatic small-cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
- Associated Conditions
- Metastatic Lung Small Cell Carcinoma
- Associated Therapies
- -
Latest Stock News & Market Updates
Jazz Pharmaceuticals (JAZZ) is a global biopharmaceutical company focusing on sleep, hematology/oncology, and pain, with notable products like Xyrem, Xywav, Zepzelca, Rylaze, and Epidiolex. In 2023, it achieved $3.8 billion in revenue, completed a Phase 3 trial for Zepzelca, and advanced zanidatamab development. With $1.6 billion in cash and $5.8 billion in debt, Jazz continues to innovate through R&D and strategic acquisitions, partnering with BeiGene and Life Science Cares.
Patients with Extensive-Stage SCLC May Benefit From Higher I-DXd Dose
Heavily pretreated ES-SCLC patients benefited from ifinatamab deruxtecan (I-DXd), with a 12 mg/kg dose showing higher overall response rate (54.8%) vs. 8 mg/kg (26.1%). Disease control rates were over 80% in both groups, suggesting I-DXd's potential as a treatment option for ES-SCLC.
Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
Jazz Pharmaceuticals to present five abstracts at ESMO Congress 2024, including new data on zanidatamab for HER2-positive mGEA and mCRC, and Zepzelca for relapsed SCLC.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath